Inhibition of β2-ARs can reduce the concentration of cAMP and inhibit the activation of protein kinase A (PKA), thereby affecting the expression of downstream transcription factors, such as CREB and NF-KB, leading to inhibition of tumor cell proliferation. The gene discussed is NFKB1; the disease is neoplasm.